Procurement teams evaluating insertable cardiac monitors face a decision that extends well beyond unit price or insertion convenience. The relevant comparison points sit in documentation that is unevenly public: electrogram sensing architecture, episode transmission paths, remote programming capacity, and the coding and coverage structures that determine downstream cost. A defensible comparison requires separating manufacturer claims that are supported by published performance data from those resting on internal files, and recognizing where the evidence base simply stops. This guide organizes that evaluation around specific technical decision points, using the Medtronic LINQ II and Abbott Confirm Rx as documented reference products while flagging settings where a different monitor might be appropriate.
Start from the sensing and detection architecture
The first decision point is how the device is intended to detect arrhythmias. Medtronic describes the LINQ II ICM as incorporating AccuRhythm AI algorithms for long-term heart monitoring [1]. The manufacturer also states that the LINQ family offers an AF detection accuracy rate of 99.7% [2]. That figure is a vendor claim tied to promotional documentation; procurement staff should request the underlying reference and study design rather than treat it as an independent comparator. Abbott describes the Confirm Rx ICM with SharpSense technology as designed with more discriminators to improve specificity while maintaining high relative sensitivity, citing a data-on-file report [5]. These are not equivalent metrics, and they cannot be directly compared without access to the same endpoint definitions and populations.
Published independent data illustrate the practical limits. A 2019 clinical evaluation of a small ICM with a long sensing vector reported 93.6% sensitivity for AF duration and an episode-based positive predictive value of 72.5%, with false positives mostly arising from irregular rhythms misclassified as atrial fibrillation [3]. The authors note the estimation was limited by available Holter reference data and the study did not assess long-term sensing performance [3]. This study is not a head-to-head trial of current commercial products, but it demonstrates the variables that matter in procurement: sensing vector configuration, false-positive drivers, and the weakness of single-week or short-duration performance claims.
Connectivity and remote management differ in workflow consequences
The second decision point is how data leaves the patient and how programming changes return. Medtronic markets LINQ II as the first ICM with remote programming, enabled through the CareLink network and MyCareLink Relay or MyCareLink Heart app [1]. The manufacturer describes clinician-initiated reprogramming with device settings updating without an office visit [1]. For a hospital system consolidating follow-up into centralized nursing workflows, that may reduce visit scheduling burden, but the claim is promotional and should be validated against the institution's existing CareLink infrastructure. Abbott's Confirm Rx ICM connects directly to the myMerlin Mobile App via Bluetooth, with the app acting as transmitter and symptom recorder and transmitting per a clinician-set schedule [5]. That architecture removes a bedside communicator but makes the patient's phone a dependency in the transmission path.
The evidence comparing connection models is thin. A 2024 systematic review of smart device interface remote monitoring versus radiofrequency bedside monitoring retrieved only two articles after screening 3,222 records [8]. The authors described the evidence as encouraging but explicitly stated that further research on cost-effectiveness and long-term clinical outcomes is needed [8]. Procurement teams should therefore avoid treating smartphone-based connectivity as inherently equivalent to dedicated communicator pathways. The correct question is whether the institution's patient population reliably maintains a compatible phone, and whether the clinical service can absorb connection-issue alerts that Abbott documents as patient-facing notifications [5].
Short-form criteria for an ICM procurement worksheet
Institutional buyers can use this working set of questions to structure vendor responses and internal scoring. Request the device's physical specifications, including mass, volume, dimensions, electrode surface area, and inter-electrode distance as Medtronic lists for LINQ II [1], and require the same standardized parameters from any competitor. Confirm the remote programming capability and the mechanism by which settings update without an office visit [1]. Ask whether the transmission architecture requires a bedside communicator or a patient smartphone [1][5]. Obtain the specific MRI compatibility documentation rather than a general label, because manufacturers describe conditional environments with technical manual conditions [1][2].
Separate clinical claims from documentation. Medtronic's 99.7% AF detection accuracy figure [2] should be treated as vendor-reported until the underlying study is supplied. Abbott's SharpSense specificity claim rests on internal data [5] and requires the same scrutiny. The independent 2019 clinical evaluation, with 93.6% AF duration sensitivity and a 72.5% episode-based positive predictive value, is useful context but does not evaluate the current commercial devices under comparison [3]. Procurement should request peer-reviewed evidence specific to the model and firmware generation being purchased, and record what the vendors decline to provide as a gap in the evaluation.
Interoperability and data export are contractual, not conversational
A device can perform well clinically and still burden an EHR integration team. The HL7 FHIR R5 CardX implementation guide for cardiac implantable electronic devices, published as an STU with a status date in April 2026, is designed to improve management and outcomes by enabling the exchange of information across systems treating implanted-device patients [4]. Its stated benefits include enabling remote monitoring and timely transmission of device alerts for patients whose CIED is disconnected from their monitor [4]. Procurement should not assume any vendor product conforms; instead, the request for proposal should require a written statement on CardX IG support, because conformance determines whether disconnected-patient data surfaces in existing clinical queues or remains inside a proprietary portal.
The FHIR guide lists stakeholders including EHR, PHR, health care IT vendors, and healthcare institutions [4]. That scope does not create a regulatory mandate, and no source in this review documents which commercial ICMs currently implement the guide. A procurement team comparing LINQ II and Confirm Rx would need vendor-specific interoperability documentation that is not present in the retrieved product pages. This is a material gap: both products route data through manufacturer networks, CareLink and Merlin.net PCN respectively [1][5], and the extent to which structured FHIR export is available from those networks is an open procurement question rather than a documented feature.
Reimbursement mechanics shape total cost of ownership
The implant itself is only one component of the economic comparison. Medtronic's February 2026 reimbursement guide states that remote monitoring periods differ by device category: 90 days for pacemakers, ICDs, and CRT devices, and 30 days for subcutaneous cardiac rhythm monitors and implantable physiologic cardiac monitors [6]. That distinction directly affects how frequently remote interrogation work can be billed, and it is published vendor-provided guidance rather than an independent payer policy. Procurement teams should verify local Medicare administrative contractor and commercial payer positions before modeling monitoring revenue. The guide also identifies CPT codes 93290 and 93297 for in-person and remote evaluation of implantable cardiovascular physiologic monitors [6].
One practical staffing consideration appears in the same guide: if an industry representative provides the technical component of an in-person CIED management service, the practice is recommended to bill only the professional component using modifier 26 [6]. That recommendation affects labor economics even if device pricing is equivalent. Procurement staff evaluating LINQ II and Confirm Rx should ask which monitoring services their group can realistically bill internally and which workflows rely on manufacturer support. Neither retrieved product page supplies pricing, warranty, or service-contract terms, so any total cost comparison must come from confidential quotations rather than public documentation.
A suggested evaluation sequence for a two-vendor comparison
The following demonstration is an editorial suggestion, not a report of any institution's completed procurement. A cardiology service reviewing LINQ II and Confirm Rx could structure evaluation in four stages. Stage one requests the MRI conditions and electromagnetic interference warnings for each device, since both manufacturers document restrictions around diathermy, radiation, cautery, defibrillation, lithotripsy, therapeutic ultrasound, and radiofrequency ablation [1][2]. Stage two asks each vendor to supply the published evidence behind detection-accuracy claims, separating peer-reviewed studies from data-on-file references [2][5]. Stage three maps connectivity dependencies: LINQ II's remote programming through CareLink against Confirm Rx's smartphone-centric myMerlin path [1][5]. Stage four obtains written interoperability statements addressing HL7 CardX guidance [4].
Scoring should use pass-gate criteria rather than a single winner. A site with many patients lacking reliable smartphones would likely weigh the remote programming and network-based path of LINQ II differently from a younger population comfortable managing the myMerlin app [1][5]. A site with an existing CareLink integration might discount switching costs that another institution would consider decisive. The goal is to make the trade-offs explicit without asserting that either device is superior. What the public record cannot establish is long-term sensing stability, real-world episode transmission reliability, or comparative clinical outcomes between these specific models.
Sources & references
- LINQ II™ Insertable Cardiac Monitor | Medtronic · www.medtronic.com
- Reveal LINQ™ Insertable Cardiac Monitor | Medtronic · www.medtronic.com
- Clinical evaluation of a small implantable cardiac monitor with a long sensing vector - PMC · pmc.ncbi.nlm.nih.gov
- HL7 Standards Product Brief - HL7 FHIR® R5 Implementation Guide: CardX Cardiac Implantable Electronic Devices, Edition 1 | HL7 International · www.hl7.org
- Confirm Rx Insertable Cardiac Monitor Product Overview | Abbott · www.cardiovascular.abbott
- [PDF] Cardiac implantable electronic device management services · www.medtronic.com
- Cardiac Monitor Guidance (including Cardiotachometer and Rate Alarm) - Guidance for Industry | FDA · www.fda.gov
- Remote monitoring of cardiac implantable electronic devices using smart device interface versus radiofrequency‐based interface: A systematic review - PMC · pmc.ncbi.nlm.nih.gov